

Product datasheet for TL501056

Igf1r Mouse shRNA Plasmid (Locus ID 16001)

Product data:

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product Type:	shRNA Plasmids
Product Name:	lgf1r Mouse shRNA Plasmid (Locus ID 16001)
Locus ID:	16001
Synonyms:	A330103N21Rik; CD221; D930020L01; hyft; IGF-1R
Vector:	pGFP-C-shLenti (TR30023)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Lentiviral plasmids
Components:	lgf1r - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 16001). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq: UniProt ID:	<u>NM_010513</u> , <u>NM_010513.1</u> , <u>NM_010513.2</u> , <u>BC027571</u> , <u>BC062186</u> , <u>BC138868</u> , <u>BC138869</u> <u>Q60751</u>



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

lgf1r Mouse shRNA Plasmid (Locus ID 16001) – TL501056

ORIGENE

Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds Summary: IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on INK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R (By similarity). When present in a hybrid receptor with INSR, binds IGF1 (By similarity). [UniProtKB/Swiss-Prot Function] shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

shRNA Design:These shRNA constructs were designed against multiple splice variants at this gene locus. To
be certain that your variant of interest is targeted, please contact techsupport@origene.com.If you need a special design or shRNA sequence, please utilize our custom shRNA service.

PerformanceOriGene guarantees that the sequences in the shRNA expression cassettes are verified toGuaranteed:correspond to the target gene with 100% identity. One of the four constructs at minimum are
guaranteed to produce 70% or more gene expression knock-down provided a minimum
transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to
evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly
assess knockdown, the gene expression level from the included scramble control vector must
be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US